TFF Pharmaceuticals (TFFP)
(Delayed Data from NSDQ)
$2.04 USD
-0.14 (-6.42%)
Updated May 23, 2024 03:59 PM ET
After-Market: $2.04 0.00 (0.00%) 6:16 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Brokerage Reports
TFF Pharmaceuticals, Inc. [TFFP]
Reports for Purchase
Showing records 61 - 80 ( 148 total )
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Niclosamide Inhibits Omicron Replication at Easily Deliverable Lung Doses
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Niclosamide Trial Enrollment Done, 12mg Daily Selected as RP2D
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1b TFF VORI Data Shows Highly Favorable Safety & PK in Asthmatics
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Science Day: Dry Powder Vori & AUG-3387 Fill Clear Needs, Expect New Deals
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Numerous Opportunities Not Reflected In Current Market Valuation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mix and GMs Drive Upside; Raising Estimates and PT
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q21: Niclosamide In the Clinic, TFF Vori & TFF Tac Soon Starting Phase 2
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1b Shows Favorable Safety of Inhaled Voriconazole In Asthmatics
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1b Shows Favorable Safety of Inhaled Voriconazole In Asthmatics
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Publishes Encouraging Animal Data with Augmenta Bioworks for AUG-3387 mAb
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
High Inhaled Tacrolimus Multiple Dose Proves Safe - Phase 2 Start by YE21
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: Many Partners and Potential Partners, Vori and Tac Overdelivering
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J